EANM procedure guideline for treatment of refractory metastatic bone pain

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 10, 2008, Pages 1934-1940

  Bodei, Lisa ^a   Lam, Marnix ^b   Chiesa, Carlo ^c   Flux, Glenn ^d   Brans, Boudewijn ^e   Chiti, Arturo ^f   Giammarile, Francesco ^g  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

Author keywords

153Sm lexidronam; 186Re etidronate; 89Sr; Bone palliation; Guidelines; Nuclear medicine

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID RE 186; LEXIDRONAM SAMARIUM SM 153; STRONTIUM 89;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CALCIUM LIKE FLUSHING SENSATION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG UPTAKE; ELECTRON; EXTERNAL BEAM RADIOTHERAPY; FLUSHING; GAMMA RADIATION; HORMONAL THERAPY; HUMAN; NUCLEAR MEDICINE; ORGANIZATION; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SPINAL CORD COMPRESSION; SYMPTOM; TREATMENT INDICATION;

BONE NEOPLASMS; EUROPE; HUMANS; PAIN; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC;

EID: 52449095881     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0841-y     Document Type: Review

References (38)

1. S Mercadante 1997 Malignant bone pain: pathophysiology and treatment Pain 69 1 19
2. GT Krishnamurthy S Krishnamurthy 2000 Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium J Nucl Med 41 4 688 91
3. GK Edwards J Santoro AT Taylor 1994 Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89 J Nucl Med 35 1992 4
4. VJ Lewington 2005 Bone-seeking radiopharmaceuticals J Nucl Med 46 38S 47S
5. IG Finlay MD Mason M Shelley 2005 Radioisotopes for the palliation of metastatic bone cancer: a systematic review Lancet Oncol 6 6 392 400
6. AJ Taylor Jr 1994 Strontium-89 for the palliation of bone pain due to metastatic disease J Nucl Med 35 2054
7. M Farhanghi RA Holmes WA Volkert 1992 Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer J Nucl Med 33 1451 8
8. JMH De Klerk BA Zonnenberg GH Blijham 1997 Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP Anticancer Res 17 1773 8
9. IAEA. Criteria for palliation of bone metastases-clinical applications. IAEA-TECDOC-1549. IAEA, Vienna, 2007. Retrieved from http://www-pub.iaea.org/ MTCD/publications/PDF/te_1549_web.pdf.
10. C Collins JF Eary G Donaldson 1993 Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial J Nucl Med 34 1839 44
11. RG Robinson GM Blake DF Preston 1989 Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone Radiographics 9 271 81
12. SL Turner S Gruenewald N Spry on behalf of the Metastron Users Group 2001 Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer Br J Cancer 84 3 297 302
13. ND James D Bloomfield C Luscombe 2006 The changing pattern of management for hormone-refractory, metastatic prostate cancer Prostate Cancer Prostatic Dis 9 221 9
14. AJ McEwan GA Amyotte DG McGowan 1994 A retrospective analysis of the cost effectiveness of treatment with Metastron (Sr-89-Cl) in patients with prostate cancer metastatic to bone Nucl Med Common 15 499 504
15. AJ McEwan AT Porter PM Venner 1990 An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy Antibod Immunoconj Radiopharm 3 91 8
16. AT Porter AJ McEwan JE Powe 1993 Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer Int J Radiat Oncol Biol Phys 25 805 13
17. PM Quilty D Kirk JJ Bolger 1994 A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer Radiother Oncol 31 33 40
18. AL Paszkowski DJ Hewitt A Taylor Jr 1999 Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate Clin Nucl Med 24 11 852 4
19. NA Hamdy SE Papapoulos 2001 The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates Semin Nucl Med 31 1 62 8
20. MG Lam A Dahmane WH Stevens PP van Rijk JM de Klerk BA Zonnenberg 2007 Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases Eur J Nucl Med Mol Imaging 35 4 756 64
21. HM Lamb D Faulds 1997 Samarium-153-lexidronam Drugs Aging 11 413 8
22. D Fuster R Herranz J Alcover JJ Mateos F Martín S Vidal-Sicart F Pons 2000 Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm Rev Esp Med Nucl 19 4 270 274
23. O Sartor RH Reid DL Bushnell 2007 Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain Cancer 109 3 637 643
24. GO Oosterhof JT Roberts TM de Reijke SA Engelholm S Horenblas H von der Maase N Neymark M Debois L Collette 2003 Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group Eur Urol 44 5 519 526
25. FJ Papatheofanis 1999 Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy J Nucl Med 40 9 1420 1423
26. SM Tu J Kim LC Pagliaro F Vakar-Lopez FC Wong S Wen R General DA Podoloff SH Lin CJ Logothetis 20051 Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy J Clin Oncol 23 31 7904 7910
27. R Sciuto A Festa S Rea R Pasqualoni S Bergomi G Petrilli CL Maini 2002 Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial J Nucl Med 43 79 86
28. PM Windsor 2001 Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience Clin Oncol (R Coll Radiol) 13 3 219 227
29. A Zyskowski D Lamb P Morum D Hamilton C Johnson 2001 Strontium-89 treatment for prostate cancer bone metastases: does a prostate-specific antigen response predict for improved survival? Australas Radiol 45 39 42
30. LC Pagliaro ES Delpassand D Williams RE Millikan SM Tu CJ Logothetis 2003 A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases Cancer 97 12 2988 2994
31. EB Silberstein 2005 Teletherapy and radiopharmaceutical therapy of painful bone metastases Semin Nucl Med 35 2 152 158
32. Administration of Radioactive Substances Advisory Committee. Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Source. 2000. Retrieved from http://www.arsac.org.uk/ notes_for_guidence/docs/arsac_nfg.pdf.
33. EB Silberstein C Williams 1985 Strontium-89 therapy for the pain of osseous metastases J Nucl Med 26 345 348
34. I Resche JF Chatal A Pecking 1997 A dose-controlled study of 153Sm EDTMP in the treatment of patients with painful bone metastases Eur J Cancer 33 1583 1591
35. ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals, 53 Annals of the ICRP Volume 18/1-4.
36. JF Eary C Collins M Stabin C Vernon S Petersdorf M Baker S Hartnett S Ferency JJ Addison F Appelbaum EE Gordon 1993 Samarium-153-EDTMP Biodistribution and Dosimetry Estimation J Nucl Med 34 1031 1036
37. MC Graham HI Scher GB Liu SD Yeh T Curley F Daghighian SJ Goldsmith SM Larson 1997 Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer Clin Cancer Res 5 6 1307 1318
38. TJ Herold GP Gross JC Hung 1995 A technique for measurement of strontium-89 in a dose calibrator J Nucl Med Technol 23 26 28